Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity

Vitreo-Retinal Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India.
Indian Journal of Ophthalmology (Impact Factor: 0.93). 03/2007; 55(1):75-6. DOI: 10.4103/0301-4738.29505
Source: PubMed

ABSTRACT Aggressive posterior retinopathy of prematurity (formerly known as fulminate/type II/rush disease) occurs in zone 1 or posterior zone 2. Treatment involves extensive near confluent laser ablation of a large area of avascular retina. Anterior segment ischemia is a rare complication that can occur due to injury to the long posterior ciliary arteries in the horizontal meridians during aggressive posterior laser treatment. The outcome of this rare complication is very poor. This case describes a favorable outcome of intravitreal injection of bevacizumab (Avastin) in a case of anterior segment ischemia.

  • Indian Journal of Ophthalmology 01/2007; 55(6):411-2. DOI:10.4103/0301-4738.36472 · 0.93 Impact Factor
  • Indian Journal of Ophthalmology 01/2007; 55(6):488-90. DOI:10.4103/0301-4738.36502 · 0.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To report the anatomic and visual acuity response after intravitreal bevacizumab (Avastin) in patients with diffuse diabetic macular edema. Design: Prospective, interventional case series study. This study included 20 eyes of metabolically stable diabetes mellitus with diffuse diabetic macular edema with a mean age of 59 years who were treated with two intravitreal injections of bevacizumab 1.25 mg in 0.05 ml six weeks apart. Main outcome measures were 1) early treatment diabetic retinopathy study visual acuity, 2) central macular thickness by optical coherence tomography imaging. Each was evaluated at baseline and follow-up visits. All the eyes had received some form of laser photocoagulation before (not less than six months ago), but all of these patients had persistent diffuse macular edema with no improvement in visual acuity. All the patients received two injections of bevacizumab at an interval of six weeks per eye. No adverse events were observed, including endophthalmitis, inflammation and increased intraocular pressure or thromboembolic events in any patient. The mean baseline acuity was 20/494 (log Mar=1.338+/-0.455) and the mean acuity at three months following the second intravitreal injection was 20/295 (log Mar=1.094+/-0.254), a difference that was highly significant ( P =0.008). The mean central macular thickness at baseline was 492 microm which decreased to 369 microm ( P =0.001) at the end of six months. Initial treatment results of patients with diffuse diabetic macular edema not responding to previous photocoagulation did not reveal any short-term safety concerns. Intravitreal bevacizumab resulted in a significant decrease in macular thickness and improvement in visual acuity at three months but the effect was somewhat blunted, though still statistically significant at the end of six months.
    Indian Journal of Ophthalmology 03/2007; 55(6):451-5. DOI:10.4103/0301-4738.36481 · 0.93 Impact Factor
Show more